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Abstract
Background and Objectives This analysis used a popula-
tion pharmacokinetic approach to identify covariates that
influence plasma exposure of liraglutide 3.0 mg, a gluca-
gon-like peptide-1 (GLP-1) receptor agonist approved for
weight management in overweight and obese individuals.
Methods Samples for pharmacokinetic analysis were
drawn at weeks 2, 12 and 28 of the phase IIIa SCALE
Obesity and Prediabetes (N = 2339) and SCALE Diabetes
(N = 584) trials. Dose proportionality of liraglutide in
obese subjects was investigated using data from a phase II
dose-finding study (N = 331).
Results Dose-proportional exposure of liraglutide up to and
including 3.0 mg was confirmed. Body weight and sex
influenced exposure of liraglutide 3.0 mg, while age
C70 years, race, ethnicity and baseline glycaemic status did
not. Compared with a reference subject weighing 100 kg,
exposure of liraglutide 3.0 mg was 44 % lower for a subject
weighing 234 kg (90 % CI 41–47), 41 % higher for a subject
weighing 60 kg (90 % CI 37–46), and 32 % higher (90 % CI
28–35) in females than males with the same body weight.
Neither injection site nor renal function significantly influ-
enced exposure of liraglutide 3.0 mg (post hoc analysis).
Conclusion Population pharmacokinetics of liraglutide up
to and including 3.0 mg daily in overweight and obese
adults demonstrated dose-proportional exposure, and
limited effect of covariates other than sex and body weight.
These findings were similar to those previously observed
with liraglutide up to 1.8 mg in subjects with type 2 dia-
betes mellitus. Further analysis of exposure–response
relationship and its effect on dose requirements is addres-
sed in a separate publication.
Key Points
In this analysis of obese/overweight subjects with
and without type 2 diabetes mellitus, dose-
proportional exposure of liraglutide (B3.0 mg) was
confirmed.
Body weight and sex influenced exposure of
liraglutide 3.0 mg, while age C70 years, race,
ethnicity and glycaemic status did not.
Moreover, neither injection site nor renal function
influenced exposure of liraglutide 3.0 mg.
1 Background
Liraglutide is an acylated human glucagon-like peptide-1
(GLP-1) receptor agonist with 97 % amino acid sequence
homology to human GLP-1 (7–37). Liraglutide 1.8 mg
daily (Victoza; Novo Nordisk A/S, Bagsvaerd, Denmark)
is widely approved for the treatment of type 2 diabetes
mellitus (T2DM), and liraglutide 3.0 mg is approved in the
US [1], Canada [2], Europe [3] and Mexico [4] for weight
management.
In randomised clinical trials, liraglutide 3.0 mg led
to significant weight loss, weight loss-dependent
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improvement in weight-related comorbidity, and improved
glycaemic control [5, 6]. The mechanism for liraglutide-
mediated weight loss has been shown to involve an
increase in hypothalamic satiety signals coupled with a
decrease in appetite-stimulating signals, resulting in
reduced energy intake [7, 8].
Obesity, defined as a body mass index (BMI)
C30 kg m-2 [9], is associated with multiple progressive
comorbidities such as T2DM [10, 11], hypertension, high
cholesterol, stroke, heart disease, several cancer types [12,
13] and a 5- to 10-year reduction in life expectancy [14].
Obese individuals are at greater risk for numerous physical
symptoms [15–19] and psychosocial difficulties [20], and
have poorer health-related quality of life than normal-
weight individuals [21]. The individual and societal impact
of obesity makes interventions to reduce its prevalence a
public health priority [22].
Behavioral intervention using diet and exercise is typi-
cally the initial approach for weight management, but when
this is not sufficient to produce meaningful weight loss,
pharmacotherapy may be a valuable adjunct [23–25]. The
Satiety and Clinical Adiposity—Liraglutide Evidence in
non-diabetic and diabetic people (SCALE) phase IIIa
clinical trial programme investigated the efficacy and
safety of liraglutide 3.0 mg (once-daily subcutaneous
injection) as adjunct to a reduced-calorie diet and increased
physical activity. After 56 weeks, mean body weight losses
of 8.0 % (vs. 2.6 % with placebo) and 5.9 % (vs. 2.2 %
with placebo) were observed in the SCALE Obesity and
Prediabetes [5] and SCALE Diabetes [6] trials,
respectively.
The efficacy of liraglutide 3.0 mg was consistent across
various demographic subgroups. However, there was a
tendency for less weight loss in subjects with a BMI
[40 kg m-2 and greater weight loss in females versus
males. Previously, a population pharmacokinetic analysis
in patients with T2DM [26] demonstrated that body weight
and sex were relevant factors for the exposure level of
liraglutide (at doses up to 1.8 mg), suggesting that differ-
ences in clinical response to liraglutide may be associated
with differences in exposure.
This analysis demonstrated that, in overweight and
obese adults, population pharmacokinetics of liraglutide
up to and including 3.0 mg daily was similar to that
observed with liraglutide up to 1.8 mg in subjects with
T2DM, with dose-proportional exposure and limited
effect of covariates other than sex and body weight.
Characterisation of individual exposure levels and key
determinants of exposure allows for subsequent investi-
gation of the exposure–response relationship, thereby




2.1.1 Data Sources for Population Pharmacokinetic
Analysis of Liraglutide 3.0 mg
SCALE Obesity and Prediabetes (Trial 1) was a ran-
domised, double-blind, placebo-controlled, multicentre,
phase IIIa trial examining the efficacy and safety of
liraglutide 3.0 mg versus placebo, as adjunct to diet and
exercise, in obese (BMI C30 kg m-2) or overweight (BMI
C27–29.9 kg m-2) adults with at least one weight-related
comorbidity (treated or untreated hypertension and/or
dyslipidaemia) over 56 weeks. In this trial, 3731 subjects
were randomised 2:1 to liraglutide 3.0 mg (N = 2487) or
placebo (N = 1244) injections once daily, starting at
0.6 mg/day, with weekly dose increments of 0.6 mg up to a
maximum of 3.0 mg daily (Trial 1 [5]). A total of 2339
subjects from the SCALE Obesity and Prediabetes trial
were included in this population pharmacokinetic analysis.
A single blood sample for plasma liraglutide concen-
tration measurement was drawn from all subjects included
in the pharmacokinetic analysis from Trial 1, at weeks 2
(dose escalation period), 12 and 28 after randomisation.
The date, time, liraglutide dose and injection site for the
three injections prior to each blood sampling were recor-
ded. In addition, week 16 data values were included from a
substudy (N = 52; 50 maximum concentration [Cmax]
values available) in which subjects who administered
liraglutide in the evening had blood drawn for liraglutide
bioanalysis at approximately 10, 11, 12 and 14 h after
dosing, to obtain exposure values around Cmax for
liraglutide 3.0 mg.
SCALE Diabetes (Trial 2) was a randomised, double-
blind, placebo-controlled, parallel group, multicentre,
phase IIIa trial examining the efficacy and safety of
liraglutide 3.0 mg and 1.8 mg versus placebo in over-
weight or obese (BMI C27 kg m-2) adults with T2DM
(glycated haemoglobin [HbA1c] 53–86 mmol mol
-1
[7.0–10.0 %]), treated with diet and exercise alone or
combined with one to three oral hypoglycaemic agents
(OHAs), including metformin, a thiazolidinedione and/or a
sulphonylurea. Subjects in Trial 2 (N = 846) were ran-
domised 2:1:1 to liraglutide 3.0 mg (N = 423), liraglutide
1.8 mg (N = 211) or placebo (N = 212) injections once
daily, starting at 0.6 mg/day, with weekly 0.6 mg dose
increments up to a maximum of 3.0 mg/day (Trial 2 [6]).
Blood sampling was performed at weeks 2, 12 and 28
for all subjects included in the pharmacokinetic analysis
from Trial 2, as described for subjects from Trial 1. The
date, time, dose and injection site of liraglutide for the
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three injections occurring prior to each blood sampling
were recorded.
Only records with a complete (all three doses) and
unambiguous (constant dose level; only one daily dose)
dosing history for the 3 days leading up to each visit were
included; inadequate dosing history resulted in exclusion of
1185 of 8859 records from the main pharmacokinetic
analysis. The available concentration data were used to
estimate individual area under the curve (AUC) values,
using the final population pharmacokinetic model (with the
same population level parameter values as in the original
analysis).
2.1.2 Data Source for Analysis of Dose Proportionality
of Liraglutide at Doses Up to 3.0 mg
Data from 331 adults enrolled in a phase II dose-finding
trial with liraglutide and an open-label orlistat comparator
arm (Trial 3 [27]) were used in a dose-proportionality
assessment. In this 20-week, randomised, double-blind,
placebo-controlled, six-armed, parallel group, multicentre
trial, the response to a range of liraglutide doses was
examined in obese individuals (BMI C30 and
B40 kg m-2) without T2DM. Subjects included in the
dose-proportionality analysis were randomised 1:1:1:1:1:1
to receive liraglutide 1.2 mg (N = 88), 1.8 mg (N = 80),
2.4 mg (N = 77), 3.0 mg (N = 86) or placebo (N = 98)
once daily (initiated at 0.6 mg/day, with weekly 0.6 mg
increments up to the required dose) or orlistat (120 mg
thrice daily).
Blood sampling for dose proportionality assessment was
performed at week 20 during an oral glucose tolerance test
visit, in the morning, 10–14 h after dose administration the
previous evening. Samples were drawn at 0, 60 and
120 min following glucose ingestion. The time of blood
sampling relative to the previous liraglutide dose was not
recorded.
2.2 Population Pharmacokinetic Model
A prespecified approach [28] was used for the population
pharmacokinetic analysis, which included estimation of a
base model without covariates and a full model with all
covariates included. Only the full covariate model is
described here.
The population pharmacokinetic model was developed
and validated according to the US FDA and European
Medicines Agency (EMA) guidelines for pharmacokinetic
modelling [29, 30]. Full details of the model qualification
are included in the Online Resource, Sect. 1. This was a
one-compartment model with first-order absorption and
elimination. It was parameterised by absorption rate (Ka),
apparent clearance (CL/F) and apparent volume (V/F),
where covariate effects were implemented for clearance
only, as:
CL=Fi ¼ TVCL  Eweight  Edose  Esex  Eage  Eethnicity
 Edisease status  Exp gið Þ
where TVCL is the typical liraglutide apparent clear-
ance for a reference subject profile (female; \70 years
of age; 100 kg body weight [rounded value close to
mean body weight]; White, non-Hispanic or -Latino,
and without diabetes or prediabetes, taking liraglutide
3.0 mg once daily), and g describes the random
interindividual variability, assumed to be normally dis-
tributed. To ensure identifiability of the model with the
sparsely sampled data, the liraglutide absorption rate
constant was set to a value (0.0806 L/h-1) estimated
from a population pharmacokinetic model based on a
multiple-dose clinical pharmacology study in obese
subjects ([8]; data on file), and the assumption that this
parameter can be fixed without affecting the conclu-
sions was verified by sensitivity analyses. A propor-
tional error model was used to describe the residual
variability of liraglutide concentrations. Parameter esti-
mates for the full covariate model are described in the
Online Resource (Table S1).
The full covariate model was used to obtain parameter
estimates and confidence intervals (CI) for the following
covariates: age (\ or C70 years), baseline body weight
(minimum 60 kg; maximum 234 kg, relative to a 100 kg
person), sex, race (White, Black or African American,
Asian, Other [including American Indian or Alaskan
native, native Hawaiian or other Pacific Islander]), eth-
nicity (Hispanic or Latino, non-Hispanic or -Latino),
baseline glycaemic status (non-diabetic, prediabetic or with
T2DM), and liraglutide dose (1.8 or 3.0 mg).
Likelihood profiling was used to determine geometric
means and 90 % CI for each investigated covariate. Dif-
ferences in pharmacokinetic parameters were considered
relevant if the 90 % CI of the effect fell outside the stan-
dard bioequivalence limits (0.80–1.25).
Graphical data quality analyses, including goodness-of-
fit plots, were conducted prior to performing the population
pharmacokinetic analysis, as described in the Online
Resource (Sect. 2; Figs. S1, S2).
2.3 Exposure Assessment for Dose Proportionality
The exposure data from Trial 3 were obtained by esti-
mating the full population pharmacokinetic model (devel-
oped using data from Trials 1 and 2) on data from Trial 3,
with all parameters fixed. This provided individual post hoc
empirical Bayes estimates of the exposure level for sub-
jects in Trial 3, which were used to evaluate dose
proportionality.
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2.4 Post Hoc Analysis
A post hoc analysis of the effect of (1) injection site and (2)
renal function on CL/F of liraglutide was performed, using
data from Trial 1 (injection site; renal function on CL/F of
liraglutide) and Trial 2 (renal function on CL/F of
liraglutide), by comparing individual values of covariate-
adjusted CL/F. For injection-site analysis, values were
obtained from subjects injecting into the abdomen, thigh or
upper arm. Baseline renal function was determined by
estimating creatinine clearance (CrCl) using the Chronic
Kidney Disease–Epidemiology Collaboration (CKD–EPI)
equation [31]. The effects of renal function and injection
site were not part of the prespecified analysis; this post hoc
analysis is therefore presented as the primary result for the
influence of these parameters on CL/F of liraglutide.
2.5 Liraglutide Assay
Total liraglutide plasma concentration was determined
using a validated enzyme-linked immunosorbent assay
(ELISA) [32]. The lower limit of quantification (LLOQ)
was 30 pmol L-1 for the ELISAs used in Trials 1 and 2,
and 18 pmol L-1 for the ELISA used in the dose-finding
trial (Trial 3). For Trials 1 and 2, the intra- and interassay
precision was\12.9 and 9.4 %, respectively (data on file).
For Trial 3, the intra- and interassay precision was\6.5
and 10.1 %, respectively [33].
2.6 Ethical Statements
The study protocols for all trials in this analysis were
approved by local Institutional Review Boards and Ethics
Committees. All trials were conducted in accordance with
the Declaration of Helsinki [34] and Good Clinical Practice
guidelines [35], and all patients provided written informed
consent before participation.
2.7 Data Analysis Software
SPLUS, version 8.2 (TIBCO, Palo Alto, CA, USA) was
used for data-file processing, exploratory-data analysis and
plotting. NONMEM, version 7.1.2 (ICON Development
Solutions, Ellicott City, MD, USA) was used for the pop-
ulation pharmacokinetic analysis and simulation.
3 Results
This population pharmacokinetic analysis used data from
two phase IIIa trials to examine the effects of various
covariates on plasma exposure of liraglutide 3.0 mg in
overweight and obese individuals. Dose proportionality of
liraglutide at doses up to 3.0 mg in obese subjects was also
investigated using data from one phase II trial. In this
study, we present the results of each analysis.
3.1 Demographics
Tables 1 and S2 (Online Resource) show baseline demo-
graphics in all three trial populations. Subjects in the
population pharmacokinetic analysis (Table 1) had a mean
age of 47 years, and 2.5 % (n = 73) were aged C70 years.
Most subjects were female (72 %), White (85 %), and non-
Hispanic or -Latino (90 %). Mean body weight and BMI
were 106 ± 21 kg and 38 ± 7 kg m-2, respectively. In all,
20 % of subjects had T2DM (all in Trial 2), and the
majority had normal renal function or mild renal impair-
ment. In comparison, sex and age distribution in the dose-
finding trial population was similar to that in the pharma-
cokinetic analysis population, although in the former trial
almost all subjects were White (99 %), and mean body
weight (98 ± 13 kg) and BMI (35 ± 3 kg m-2) were
somewhat lower.
3.1.1 Structural Model
Parameter estimates and qualifications of the pharmacoki-
netic model are available in the Online Resource, Sect. S1.
The pharmacokinetics of liraglutide were adequately
described by a one-compartment model with first-order
absorption and first-order elimination, with CL/F ranging
from 0.9 to 1.4 L/h. The apparent clearance was 0.9 and 1.0
L/h for a non-diabetic or diabetic female, respectively, and
1.1–1.4 L/h for a non-diabetic or diabetic male, with other
covariate factors resembling those of the reference subject
(100 kg body weight, White, non-Hispanic or -Latino,
\70 years of age, taking liraglutide 3.0 mg once daily).
3.2 Dose Proportionality of Liraglutide at Doses Up
to 3.0 mg
Model-derived AUCs by dose in this population supported
dose proportionality of liraglutide up to and including
3.0 mg (Fig. 1). Demographics of subjects from the phase
II dose-finding trial included in the dose-proportionality
analysis are included in the Online Resource, Table S2.
3.3 Population Pharmacokinetic Analysis
3.3.1 Subject Baseline Characteristics
Table 1 describes the baseline demographics of subjects
included in the population pharmacokinetic analysis. Mean
body weight and BMI for all subjects were 106 kg and
38 kg m-2, respectively. As expected, despite similar
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baseline BMI in both sex groups, mean body weight was
higher in men. Overall, the majority of subjects were White
and non-Hispanic or -Latino. There was a higher propor-
tion of females among subjects included in the pharma-


























Fig. 1 Model-derived relationship between liraglutide AUC and dose
in obese individuals. Data shown are from the phase II dose-finding
trial (Trial 3; Astrup et al. [27]) and represent means and 95 % CI.
AUC area under the curve, CI confidence interval, N number of
subjects
Table 1 Summary of baseline characteristics for subjects included in
the pharmacokinetic evaluation
Covariate Trial 1 Trial 2 Total
[N = 2339] [N = 584] [N = 2923]
Liraglutide dose, mg [n (%)]
1.8 0 (0) 191 (32.5) 191 (6.5)
3.0 2339 (100) 393 (67.5) 2732 (93.5)
Sex [n (%)]
Female 1831 (78) 281 (48) 2112 (72)
Male 508 (22) 303 (52) 811 (28)
Age, years [n (%)]
Mean (SD) 45.2 (12.0) 54.7 (10.5) 47.1 (12.3)
C75 4 (0.2) 9 (1.5) 13 (0.4)
70–74 32 (1.4) 28 (4.8) 60 (2.1)
65–69 91 (3.9) 67 (11.5) 158 (5.4)
18–64 2212 (94.5) 480 (82.2) 2692 (92.1)
Race [n (%)]a
White 1989 (85) 493 (84.4) 2482 (84.9)
Black/African American 222 (9.5) 61 (10.4) 283 (9.7)
Asian 82 (3.5) 14 (2.4) 96 (3.3)
Other 46 (2.0) 16 (2.8) 62 (2.1)
Ethnic group [n (%)]
Hispanic or Latino 246 (10.5) 60 (10.3) 306 (10.5)
Non-Hispanic or -Latino 2093 (89.5) 524 (89.7) 2617 (89.5)
Mean body weight, kg
Overall population
Mean (SD) 106 (21) 106 (22) 106 (21)
Range 65–234 60–199 30–234
Females
Mean (SD) 102 (19) 100 (19) 102 (19)
Range 65–218 60–167 60–218
Males
Mean (SD) 121 (24) 112 (22) 118 (24)
Range 79–234 75–199 75–234
BMI, kg m22
Overall population
Mean (SD) 38 (6) 37 (7) 38 (7)
Range 27–77 27–68 27–77
Females
Mean (SD) 38 (6) 38 (7) 38 (6)
Range 27–77 27–68 27–77
Males
Mean (SD) 38 (7) 36 (7) 38 (7)
Range 27–70 27–61 27–70
BMI categories [n (%)]
\29.9 60 (2.6) 77 (13.2) 137 (4.7)
30–34.9 765 (32.7) 181 (31.0) 946 (32.4)
35–39.9 730 (31.2) 148 (25.3) 878 (30.0)
C40 784 (33.5) 178 (30.5) 962 (32.9)
Table 1 continued
Covariate Trial 1 Trial 2 Total
[N = 2339] [N = 584] [N = 2923]
Glycaemic status [n (%)]
Normoglycaemic 897 (38.3) 0 (0) 897 (30.7)
Prediabetic 1442 (61.7) 0 (0) 1442 (49.3)
Type 2 diabetes 0 (0) 584 (100) 584 (20.0)
Creatinine clearance, ml/min (degree of renal impairment)
C90 (normal) 1194 (51) 295 (51) 1489 (51)
C60 and\90 (mild) 1045 (45) 236 (40) 1281 (44)
C30 and\60 (moderate) 99 (4) 52 (9) 151 (5)
\30 (severe) 1 (0) 1 (0) 2 (0.0)
Injection site [n (%)]b
Abdomen 1768 (75.6) NA
Thigh 452 (19.3)
Upper arm 113 (4.8)
Other 6 (0.3)
BMI body mass index, NA not applicable, SD standard deviation
a The ‘Other’ race group for the covariate analysis included ‘Amer-
ican Indian or Alaskan Native’, ‘Native Hawaiian or other Pacific
Islander’ and any ‘Other’
b Post hoc analysis, analysed in Trials 1 and 2
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3.3.2 Covariate Analysis
The covariate analysis results were summarised for steady-
state liraglutide exposure (AUC24) relative to exposure for
a reference subject (Table 1). The between-subject vari-
ability for liraglutide CL/F (hence dose-normalised AUC)
was 34.8 % coefficient of variation (CV), which was
reduced to 24.7 % CV when the predefined covariates for
liraglutide CL/F were included in the population pharma-
cokinetic model.
Body weight and sex significantly impacted dose-nor-
malised liraglutide exposure (Fig. 2), whereas age, race,
ethnicity, glycaemic status, dose, injection site and renal
function did not (additional data for exposure by renal
function is included in Online Resource Fig. S3). The
analysis also showed similar dose-normalised exposure for
the liraglutide 3.0 mg and 1.8 mg groups, indicating dose
proportionality in the dose range 1.8–3.0 mg, consistent
with results from the phase II dose-finding trial (Fig. 1).
3.3.3 Effect of Body weight
Mean liraglutide exposure appeared to decrease with
increasing body weight (Online Resource Fig. S1), and this
was confirmed in the population pharmacokinetic analysis
(Fig. 2). Compared with a reference subject weighing
100 kg, higher body weight was associated with decreased
liraglutide exposure, and lower body weight was associated
with increased exposure; for a 234 kg subject (the highest
observed body weight in the dataset), liraglutide exposure
was 44 % lower (78 % higher CL/F). Conversely, for a
60 kg subject (the lowest observed body weight in the
dataset), liraglutide exposure was 41 % higher (29 % lower
CL/F). The 90 % CI values were outside of the predefined
limits for bioequivalence for both the highest (234 kg) and
lowest (60 kg) body weight values, indicating an effect of
body weight on liraglutide exposure. Exposure by baseline
BMI revealed a less clear relationship. Graphical analysis
demonstrated negligible difference between subjects with
Covariates Parameter Reference Estimated mean AUC ratio and 90% CI



















































Fig. 2 Influence of covariates on exposure expressed as change in
relative steady-state dose-normalised liraglutide exposure (AUC24/-
dose). Reference subject profile: female, below 70 years of age,
100 kg body weight, White, non-Hispanic or -Latino, without
diabetes or prediabetes, dosed by liraglutide 3.0 mg once daily. The
parameter ‘body weight’ shows the highest and lowest in the dataset.
Mild and moderate/severe renal impairment were defined as C60 and
\90 ml min-1 and C30 and \60 ml min-1, respectively, and ‘no
renal impairment’ was defined as C90 ml/min. Dotted lines indicate
the interval used for bioequivalence testing, for comparison. The
column to the right shows geometric mean relative exposures with
90 % CI obtained by likelihood profiling. Covariates above the solid
horizontal line were prespecified, and parameters below the solid line
were analyzed post hoc. CI confidence interval, AUC area under the
curve
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high and low BMI when body weight was matched (data
not shown). Additional statistical analyses based on post
hoc estimates confirmed that, for simultaneous investiga-
tion of body weight and BMI, the influence of body weight
on exposure was highly significant (p\ 0.0001), and of
similar magnitude as in the main analysis. By contrast, the
BMI influence was small and of borderline significance
(p * 0.03). These findings suggest that absolute body-
weight, rather than obesity per se, is the better predictor of
liraglutide exposure.
3.3.4 Effect of Sex
Liraglutide exposure was 24 % lower in males than in
females of comparable body weight (Fig. 2), which cor-
responds to 32 % greater exposure in females compared
with males at comparable body weight. The effect of sex
on exposure was independent of the effect of body weight
(Online Resource Fig. S4). Since the 90 % CI for this
effect was outside of the bioequivalence limits, sex was
considered to have a pharmacokinetically relevant effect on
liraglutide exposure.
3.3.5 Effect of Trial: Glycaemic Status
Subjects with T2DM were found to have 16 % lower
liraglutide exposure than normoglycaemic subjects, while
subjects with prediabetes had similar mean exposure to
normoglycaemic subjects (Fig. 2). The 90 % CI for subjects
with T2DM versus normoglycaemic subjects fell narrowly
within the bioequivalence limits and were therefore not
considered pharmacokinetically relevant. However, gly-
caemic status was confounded by trial as all subjects with
T2DM originated from Trial 2. Therefore, a trial effect
cannot be excluded. Conversely, subjects with prediabetes
had similar liraglutide exposure to normoglycaemic subjects;
however, in this case both groups originated from Trial 1.
The geometric mean of the individual apparent clear-
ance estimates in the three studies was 0.94, 1.22 and
0.93 L/h for Trials 1, 2 and 3, respectively. This confirms
similarity between the trials in subjects without diabetes
(Trials 1 and 3), and higher clearance values for Trial 2, in
subjects with diabetes. The covariate-adjusted clearance
estimate was similar across the three trials (geometric mean
0.86, 0.86, and 0.88 L/h, respectively), confirming that the
estimated covariate factors adequately accounted for dif-
ferences between trials.
3.3.6 Effect of Body Weight on Exposure: By Sex
and Baseline Glycaemic Status
Exposure levels at steady-state concentrations of liraglutide
3.0 mg overlapped in male and female subjects. However,
in general, males are heavier than females and therefore the
combined effects of sex and body weight contribute to a
generally lower exposure in males versus females. The
relationship among exposure, body weight and sex is
shown in Fig. 3a. Likewise, individuals with T2DM gen-
erally had lower exposure than those with normoglycaemia
or prediabetes at all body weights (Fig. 3b).
3.3.7 High and Low Exposure Scenarios Including
Additional Covariates
A ‘high-exposure scenario’ was generated using a female
of body weight 60 kg (lowest observed body weight in the
pharmacokinetic dataset) without T2DM using injection
site ‘upper arm’ and additional covariates expected to give
the highest exposure (C70 years of age, Black, non-His-
panic). A ‘low-exposure scenario’ was generated using a
male with body weight 234 kg (highest observed body
weight in the pharmacokinetic dataset) with T2DM using
injection site ‘thigh’, and additional covariates expected to
give the lowest exposure (\70 years of age, White, His-
panic). Predicted liraglutide exposure values (AUC) for the
high- and low-exposure scenarios were 1631 and
297 nM h, respectively. These predicted exposure levels
were covered by the actual observed exposure levels.
3.3.8 Exposure Comparison: Liraglutide 3.0 mg
in Overweight/Obese Subjects Versus 1.8 mg
in Subjects with Type 2 Diabetes Mellitus
Liraglutide 1.8 mg is approved for use in subjects with
T2DM, and safety data are available both from the clinical
trial programme and postmarketing experience. To evalu-
ate the applicability of safety data for liraglutide 1.8 mg in
subjects with T2DM with liraglutide 3.0 mg in overweight/
obese subjects, an exposure comparison was undertaken.
The predicted estimated exposure distribution associated
with liraglutide 3.0 mg in overweight/obese subjects in
Trials 1 and 2 was compared with the estimated exposure
of liraglutide 1.8 mg in subjects with T2DM in a previous
phase III trial [26]. As shown in Fig. 4, there is substantial
overlap in exposures with liraglutide 3.0 and 1.8 mg when
used for weight management and treatment of T2DM,
respectively, in overweight/obese subjects with and with-
out T2DM; approximately 16 % of the overweight/obese
population receiving 3.0 mg reach exposures higher than
any exposure in subjects with T2DM treated with 1.8 mg.
Approximately one-third of the difference in exposure
between Trials 1 and 2 (29 % higher exposure in Trial 1)
could be explained by the higher proportion of females in
Trial 1 (78 vs. 48 %). The remaining 19 % may be
attributed to differences in exposure in subjects with and
without T2DM.
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4 Discussion
This analysis demonstrated that exposure of liraglutide,
within the dose range 1.2–3.0 mg, is dose proportional in
obese adults. Furthermore, the population pharmacokinetic
assessment established a plasma clearance value for
liraglutide 3.0 mg in overweight and obese adults of
between 0.9 and 1.4 L/h, and demonstrated that exposure
of liraglutide 3.0 mg in an overweight or obese population
is mainly impacted by two key covariates—body weight
and sex.
These findings are consistent with the established
pharmacokinetic properties of liraglutide at lower doses
[36]. Dose-proportional exposure has been demonstrated in
the 0.6–1.8 mg dose range in healthy adults [37, 38] and
those with T2DM [39, 40]. Furthermore, body weight and
sex (but not age, race or ethnicity) were previously found
to be relevant covariates for liraglutide (1.2–1.8 mg)
clearance, and hence exposure, in a population pharma-
cokinetic analysis in subjects with T2DM and mean body
weight of 90 kg [26].
Reasons for the lower weight-adjusted clearance of
liraglutide in females than males, and the effects of dif-
ferences in body composition and other factors, have yet to
be determined. Further analysis of the exposure–response
relationship demonstrated increasing weight loss response
at increasing exposure levels throughout the exposure
range, with clear effects apparent in the low exposure
range. With the exception of gastrointestinal tolerability,
safety and tolerability were not exposure-dependent [41].
Therefore, exposure–response analysis supported use of the
highest tested dose of liraglutide (3.0 mg) in all subpopu-
lations, and did not support differential dosing in males
versus females or in heavier versus lighter individuals [41].
Liraglutide is endogenously metabolised without a
specific organ as a major route of elimination [42]. In
accordance with this, post hoc analysis demonstrated that
clearance of liraglutide 3.0 mg is not impacted by mild
(CrCl C60 and\90 ml min-1) or moderate (CrCl C30 and
\60 ml min-1) renal impairment, although we recognise
that use of epidermal growth factor receptor (eGFR) may
have led to overestimation of true GFR in this obese
population [43]. While this suggests that dose adjustment
of liraglutide 3.0 mg is not required in renal impairment (as
is also the case for liraglutide 1.8 mg) [44, 45], experience
with liraglutide 3.0 mg in patients with severe renal
impairment (CrCl \30 ml min-1), including end-stage
renal disease, is limited. Use in this group is therefore not
recommended [1], and caution is advised when initiating or
escalating doses of liraglutide in these patients [1]. The
post hoc analysis also found no difference in CL/F values
for liraglutide across injection sites (abdomen, thigh or
















































Fig. 3 Liraglutide exposure versus body weight stratified by a sex
and b glycaemic status. Data are dose-normalised mean AUC values
with 95 % CI for quantiles of baseline body weight (large symbols)
and individual exposure estimates (small symbols). Lines are model-
based relationships adjusted for other covariate effects. AUC area
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Liraglutide 3.0 mg (Trial 2 [6])
1000
Fig. 4 Exposure distribution (patient frequency) predicted for
liraglutide 3.0 mg in overweight/obese subjects with (Trial 2 [6])
and without T2DM (Trial 1 [5]) compared with liraglutide 1.8 mg in
subjects with T2DM [26]. AUC area under the curve, T2DM type 2
diabetes mellitus
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patient preference. Since the effects of adding renal func-
tion and/or injection site to the model are minimal, and the
shrinkage in clearance is small, these effects would remain
eligible if the prespecified model was revised to include
these parameters.
Covariate analysis showed that subjects with low body
weight will achieve higher liraglutide exposure than sub-
jects with high body weight. Therefore, the liraglutide
exposure level was compared between the weight man-
agement programme (with the higher dose 3.0 mg and
heavier subjects [body weight range 60–234 kg]) and
liraglutide 1.8 mg in subjects with T2DM (phase III trial
with body weight range 40–160 kg [26]). The substantial
overlap in exposures in the two programmes indicates that
safety data obtained with liraglutide 1.8 mg can usefully
inform dosing with liraglutide 3.0 mg. To further evaluate
the safe use of liraglutide in subjects with overweight/
obesity, in particular for exposure levels exceeding the
range obtained with 1.8 mg, an exposure–response evalu-
ation was conducted for selected safety parameters and has
been published separately [41].
5 Conclusions
Exposure of liraglutide up to and including 3.0 mg in
overweight and obese adults is dose proportional. For
liraglutide 3.0 mg, sex and body weight are the main
baseline covariates influencing exposure, while age
C70 years, race, ethnicity, glycaemic status, mild-to-
moderate renal impairment, injection site and dose are not
considered pharmacokinetically relevant. Further expo-
sure–response analyses in relevant subgroups are required
to support dosing recommendations of liraglutide 3.0 mg
for weight management.
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